earlier i talked to mohamed mir who's a viral infection and vaccine expert at lancaster university in the u.k. i asked him how unusual it is that a vaccine still in phase 3 clinical trials is being rolled out for mass vaccination having a deploy a vaccine at that scale a 100000 or even more than that people don't have in fact that i conduct is there a continuous moving forward test because vaccines are required to get us and that's one of the reason that we took a doctor long time to come up with a vaccine that we can all trust so the vaccine that is not the best you tested which certainly be concerning moving forward because it's not just the russia itself that would be setting an example for other countries which if it haunts the vaccine has a tendency on board for more efforts to have a high coverage because let me make it a concern it's not just having the vaccine concern it that all we can eat and hope of widely we can deploy it because until we don't immunized 75 percent of the people they are fact of the vaccine would be significantly lower which we don't really want to see tha